title: Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections.
abstract: Roxithromycin 300 mg once daily was compared with clarithromycin 250 mg b.i.d. in an open randomized trial in 200 patients with upper respiratory tract infection: sinusitis, pharyngotonsillitis, and otitis media. Average treatment duration was 9 days. Roxithromycin was more effective (p less than 0.01) particularly in otitis media and pharyngotonsillitis, and better tolerated (only 4% side effects, p less than 0.05).
authors.affiliation: Division of ORL, Fatebenefratelli Hospital, Rome, Italy.
authors.forename: E
authors.initials: E
authors.lastname: de Campora
authors.forename: A
authors.initials: A
authors.lastname: Camaioni
authors.forename: M
authors.initials: M
authors.lastname: Leonardi
authors.forename: P
authors.initials: P
authors.lastname: Fardella
authors.forename: M
authors.initials: M
authors.lastname: Fiaoni
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017291:Clarithromycin; D004361:Drug Tolerance; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010033:Otitis Media / Q000188:drug therapy; D010612:Pharyngitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D015575:Roxithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012852:Sinusitis / Q000188:drug therapy; D014069:Tonsillitis / Q000188:drug therapy
chemical_list: D015575:Roxithromycin; D004917:Erythromycin; D017291:Clarithromycin